Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US5733886 | BAUSCH | Compositions of clindamycin and benzoyl peroxide for acne treatment |
Mar, 2015
(9 years ago) | |
US8663699 | BAUSCH | Topical pharmaceutical formulations containing a low concentration of benzoyl peroxide in suspension in water and a water-miscible organic solvent |
Jun, 2029
(5 years from now) | |
US10220049 | BAUSCH | Topical pharmaceutical formulations containing a low concentration of benzoyl peroxide in suspension in water and a water-miscible organic solvent |
Jun, 2029
(5 years from now) | |
US10624918 | BAUSCH | Topical pharmaceutical formulations containing a low concentration of benzoyl peroxide in suspension in water and a water-miscible organic solvent |
Jun, 2029
(5 years from now) | |
US8895070 | BAUSCH | Topical pharmaceutical formulations containing a low concentration of benzoyl peroxide in suspension in water and a water-miscible organic solvent |
Jun, 2029
(5 years from now) | |
US9078870 | BAUSCH | Topical pharmaceutical formulations containing a low concentration of benzoyl peroxide in suspension in water and a water-miscible organic solvent |
Jun, 2029
(5 years from now) | |
US8288434 | BAUSCH | Topical pharmaceutical formulations containing a low concentration of benzoyl peroxide in suspension in water and a water-miscible organic solvent |
Aug, 2029
(5 years from now) |
Drugs and Companies using BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE ingredient
Market Authorisation Date: 23 October, 2008
Treatment: Treatment of acne; Topical treatment of acne vulgaris in patients 12 years or older
Dosage: GEL;TOPICAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US7696159 | BAUSCH | Treatment for basal cell carcinoma |
Apr, 2024
(26 days ago) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US7696159 (Pediatric) | BAUSCH | Treatment for basal cell carcinoma |
Oct, 2024
(5 months from now) |
Drugs and Companies using IMIQUIMOD ingredient
Market Authorisation Date: 27 February, 1997
Treatment: Works through the induction of interferon and other cytokines
Dosage: CREAM;TOPICAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US7572935 | BAUSCH | Modified release formulations of a bupropion salt |
Jun, 2026
(2 years from now) | |
US7569610 | BAUSCH | Modified release formulations of a bupropion salt |
Jun, 2026
(2 years from now) | |
US7645802 | BAUSCH | Bupropion hydrobromide and therapeutic applications |
Jun, 2026
(2 years from now) | |
US7662407 | BAUSCH | Modified release formulations of a bupropion salt |
Jun, 2026
(2 years from now) | |
US7585897 | BAUSCH | Modified release formulations of a bupropion salt |
Jun, 2026
(2 years from now) | |
US7649019 | BAUSCH | Modified release formulations of a bupropion salt |
Jun, 2026
(2 years from now) | |
US7241805 | BAUSCH | Modified release formulations of a bupropion salt |
Jun, 2026
(2 years from now) | |
US7671094 | BAUSCH | Bupropion hydrobromide and therapeutic applications |
Jun, 2026
(2 years from now) |
Drugs and Companies using BUPROPION HYDROBROMIDE ingredient
Market Authorisation Date: 23 April, 2008
Treatment: Treatment of major depressive disorder by dosing at intervals of 24 hours
Dosage: TABLET, EXTENDED RELEASE;ORAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US6517847 | BAUSCH | Topical gel delivery system |
Aug, 2020
(3 years ago) | |
US11679116 | BAUSCH | Topical compositions and methods for treating psoriasis |
Jun, 2036
(12 years from now) | |
US11311482 | BAUSCH | Topical compositions and methods for treating skin diseases |
May, 2038
(14 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Product(NP) | Dec 18, 2022 |
Drugs and Companies using TAZAROTENE ingredient
Market Authorisation Date: 18 December, 2019
Treatment: Topical treatment of acne vulgaris in patients 9 years of age and older
Dosage: LOTION;TOPICAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US6517847 | BAUSCH | Topical gel delivery system |
Aug, 2020
(3 years ago) | |
US8809307 | BAUSCH | Pharmaceutical formulations containing corticosteroids for topical administration |
Nov, 2031
(7 years from now) | |
US10478502 | BAUSCH | Pharmaceutical formulations containing corticosteroids for topical administration |
Nov, 2031
(7 years from now) | |
US11839656 | BAUSCH | Pharmaceutical formulations containing corticosteroids for topical administration |
Nov, 2031
(7 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Product(NP) | Nov 06, 2021 |
Drugs and Companies using HALOBETASOL PROPIONATE ingredient
Market Authorisation Date: 06 November, 2018
Treatment: Topical treatment of plaque psoriasis in adults
Dosage: LOTION;TOPICAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10220049 | BAUSCH | Topical pharmaceutical formulations containing a low concentration of benzoyl peroxide in suspension in water and a water-miscible organic solvent |
Jun, 2029
(5 years from now) | |
US9561208 | BAUSCH | Topical pharmaceutical formulations containing a low concentration of benzoyl peroxide in suspension in water and a water-miscible organic solvent |
Jun, 2029
(5 years from now) | |
US10624918 | BAUSCH | Topical pharmaceutical formulations containing a low concentration of benzoyl peroxide in suspension in water and a water-miscible organic solvent |
Jun, 2029
(5 years from now) | |
US8288434 | BAUSCH | Topical pharmaceutical formulations containing a low concentration of benzoyl peroxide in suspension in water and a water-miscible organic solvent |
Aug, 2029
(5 years from now) | |
US11389467 | BAUSCH | Topical compositions |
Dec, 2040
(16 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Product(NP) | Oct 20, 2026 |
Drugs and Companies using ADAPALENE; BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE ingredient
Market Authorisation Date: 20 October, 2023
Treatment: Topical treatment of acne vulgaris in adult and pediatric patients 12 years of age and older
Dosage: GEL;TOPICAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US5439689 | BAUSCH | Diltiazem formulation |
Aug, 2012
(11 years ago) |
Drugs and Companies using DILTIAZEM HYDROCHLORIDE ingredient
Market Authorisation Date: 10 August, 1992
Treatment: Treatment of hypertension and angina pectoris
Dosage: CAPSULE, EXTENDED RELEASE;ORAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US5529791 | BAUSCH | Extended release form of diltiazem |
Jun, 2013
(10 years ago) | |
US7108866 | BAUSCH | Chronotherapeutic diltiazem formulations and the administration thereof |
Dec, 2019
(4 years ago) | |
US6923984 | BAUSCH | Cushioning wax beads for making solid shaped articles |
Feb, 2021
(3 years ago) |
Drugs and Companies using DILTIAZEM HYDROCHLORIDE ingredient
Market Authorisation Date: 06 February, 2003
Treatment: Treatment of hypertension and angina pectoris
Dosage: TABLET, EXTENDED RELEASE;ORAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US6387383 | BAUSCH | Topical low-viscosity gel composition |
Aug, 2020
(3 years ago) |
Drugs and Companies using CLINDAMYCIN PHOSPHATE ingredient
Market Authorisation Date: 27 November, 2000
Treatment: Topical treatment of acne vulgaris
Dosage: GEL;TOPICAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US5462740 | BAUSCH | Rectally-administered, epileptic-seizure-inhibiting composition |
Sep, 2013
(10 years ago) |
Drugs and Companies using DIAZEPAM ingredient
Market Authorisation Date: 29 July, 1997
Treatment: NA
Dosage: GEL;RECTAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US5462740 | BAUSCH | Rectally-administered, epileptic-seizure-inhibiting composition |
Sep, 2013
(10 years ago) |
Drugs and Companies using DIAZEPAM ingredient
Market Authorisation Date: 29 July, 1997
Treatment: NA
Dosage: GEL;RECTAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US6517847 | BAUSCH | Topical gel delivery system |
Aug, 2020
(3 years ago) | |
US8809307 | BAUSCH | Pharmaceutical formulations containing corticosteroids for topical administration |
Nov, 2031
(7 years from now) | |
US11839656 | BAUSCH | Pharmaceutical formulations containing corticosteroids for topical administration |
Nov, 2031
(7 years from now) | |
US10478502 | BAUSCH | Pharmaceutical formulations containing corticosteroids for topical administration |
Nov, 2031
(7 years from now) | |
US11648256 | BAUSCH | Topical compositions and methods for treating psoriasis |
Jun, 2036
(12 years from now) | |
US10251895 | BAUSCH | Topical compositions and methods for treating psoriasis |
Jun, 2036
(12 years from now) | |
US10426787 | BAUSCH | Topical compositions and methods for treating psoriasis |
Jun, 2036
(12 years from now) | |
US11679115 | BAUSCH | Topical compositions and methods for treating psoriasis |
Jun, 2036
(12 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Product(NP) | Apr 25, 2022 |
Drugs and Companies using HALOBETASOL PROPIONATE; TAZAROTENE ingredient
Market Authorisation Date: 25 April, 2019
Treatment: Topical treatment of plaque psoriasis in adults
Dosage: LOTION;TOPICAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US6352998 | BAUSCH | Pharmaceutical compositions |
Oct, 2015
(8 years ago) | |
US6352998 (Pediatric) | BAUSCH | Pharmaceutical compositions |
Apr, 2016
(8 years ago) | |
US5912238 | BAUSCH | Heteroatoms-containing tricyclic compounds |
Jun, 2016
(7 years ago) | |
US5912238 (Pediatric) | BAUSCH | Heteroatoms-containing tricyclic compounds |
Dec, 2016
(7 years ago) | |
US6423722 | BAUSCH | Crystalline macrolides and process for their preparation |
Jun, 2018
(5 years ago) | |
US6423722 (Pediatric) | BAUSCH | Crystalline macrolides and process for their preparation |
Dec, 2018
(5 years ago) |
Drugs and Companies using PIMECROLIMUS ingredient
Market Authorisation Date: 13 December, 2001
Treatment: NA
Dosage: CREAM;TOPICAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US5733874 | BAUSCH | Stable dry powders |
Mar, 2015
(9 years ago) |
Drugs and Companies using DESIRUDIN RECOMBINANT ingredient
Market Authorisation Date: 04 April, 2003
Treatment: NA
Dosage: INJECTABLE;SUBCUTANEOUS
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US7214506 | BAUSCH | Method for treating onychomycosis |
Feb, 2026
(1 year, 9 months from now) | |
US10512640 | BAUSCH | Compositions and methods for treating diseases of the nail |
Jan, 2028
(3 years from now) | |
US11213519 | BAUSCH | Compositions and methods for treating diseases of the nail |
Jan, 2028
(3 years from now) | |
US9877955 | BAUSCH | Compositions and methods for treating diseases of the nail |
Jan, 2028
(3 years from now) | |
US10828369 | BAUSCH | Compositions and methods for treating diseases of the nail |
Jan, 2028
(3 years from now) | |
US9566272 | BAUSCH | Compositions and methods for treating diseases of the nail |
Jan, 2028
(3 years from now) | |
US8039494 | BAUSCH | Compositions and methods for treating diseases of the nail |
Jul, 2030
(6 years from now) | |
US9861698 | BAUSCH | Compositions and methods for treating diseases of the nail |
Jul, 2030
(6 years from now) | |
US10105444 | BAUSCH | Compositions and methods for treating diseases of the nail |
Jul, 2030
(6 years from now) | |
US9302009 | BAUSCH | Compositions and methods for treating diseases of the nail |
Oct, 2030
(6 years from now) | |
US8486978 | BAUSCH | Compositions and methods for treating diseases of the nail |
Oct, 2030
(6 years from now) | |
US9662394 | BAUSCH | Stabilized efinaconazole compositions |
Oct, 2034
(10 years from now) | |
US10864274 | BAUSCH | Stabilized efinaconazole formulations |
Oct, 2034
(10 years from now) | |
US10342875 | BAUSCH | Stabilized efinaconazole compositions |
Oct, 2034
(10 years from now) | |
US11654139 | BAUSCH | Anti-infective methods, compositions, and devices |
Oct, 2034
(10 years from now) | |
US10828293 | BAUSCH | Anti-infective methods, compositions, and devices |
Oct, 2034
(10 years from now) | |
US10478601 | BAUSCH | Applicator |
Apr, 2035
(10 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Patient Population(NPP) | Apr 27, 2023 |
New Chemical Entity Exclusivity(NCE) | Jun 06, 2019 |
Drugs and Companies using EFINACONAZOLE ingredient
NCE-1 date: 06 June, 2018
Market Authorisation Date: 06 June, 2014
Treatment: Antimycotic uses, specifically treatment of onychomycosis; Topical treatment of onychomycosis of the toenail(s) due to trichophyton rubrum and trichophyton mentagrophytes; Topical treatment of the toe...
Dosage: SOLUTION;TOPICAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US7981877 | BAUSCH | Stabilized steroid composition and method for its preparation |
Jan, 2025
(8 months from now) | |
US7378405 | BAUSCH | Stabilized steroid composition and method for its preparation |
Dec, 2026
(2 years from now) |
Drugs and Companies using HYDROCORTISONE BUTYRATE ingredient
Market Authorisation Date: 18 May, 2007
Treatment: NA
Dosage: LOTION;TOPICAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8227490 | BAUSCH | Use of 1-hydroxy-2-pyridones for the treatment of seborrheic dermatitis |
Sep, 2017
(6 years ago) | |
US7981909 | BAUSCH | Use of 1-hydroxy-2-pyridones for the treatment of seborrheic dermatitis |
Sep, 2017
(6 years ago) |
Drugs and Companies using CICLOPIROX ingredient
Market Authorisation Date: 28 February, 2003
Treatment: Treatment of seborrheic dermatitis; Treatment of seborrheic dermatitis of the scalp
Dosage: SHAMPOO;TOPICAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US5900488 | BAUSCH | Method for treating mycosis using imidazolylacetonitrile derivatives |
Jan, 2020
(4 years ago) | |
US9012484 | BAUSCH | Crystal and pharmaceutical preparation containing the same crystal |
Sep, 2033
(9 years from now) | |
US9199977 | BAUSCH | Crystal having crystal habits and pharmaceutical composition obtained by processing the crystal |
Sep, 2033
(9 years from now) | |
US9453006 | BAUSCH | Crystalline form having specific crystal habit and pharmaceutical composition containing this crystalline form as active ingredient |
Sep, 2033
(9 years from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8980931 | BAUSCH | Method of evaluating pharmaceutical preparation containing luliconazole and index substance |
Apr, 2034
(10 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Nov 14, 2018 |
New Patient Population(NPP) | Feb 20, 2021 |
Drugs and Companies using LULICONAZOLE ingredient
NCE-1 date: 14 November, 2017
Market Authorisation Date: 14 November, 2013
Treatment: Treatment of fungal infections
Dosage: CREAM;TOPICAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US5536743 | BAUSCH | Intravaginal treatment of vaginal infections with buffered metronidazole compositions |
Jul, 2013
(10 years ago) |
Drugs and Companies using METRONIDAZOLE ingredient
Market Authorisation Date: 17 August, 1992
Treatment: Method of treating bacterial vaginosis
Dosage: GEL;VAGINAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US5733886 | BAUSCH | Compositions of clindamycin and benzoyl peroxide for acne treatment |
Mar, 2015
(9 years ago) | |
US10137142 | BAUSCH | Topical pharmaceutical formulations containing a low concentration of benzoyl peroxide in suspension in water and a water-miscible organic solvent |
Jun, 2029
(5 years from now) | |
US9504704 | BAUSCH | Topical pharmaceutical formulations containing a low concentration of benzoyl peroxide in suspension in water and a water-miscible organic solvent |
Jun, 2029
(5 years from now) | |
US9561208 | BAUSCH | Topical pharmaceutical formulations containing a low concentration of benzoyl peroxide in suspension in water and a water-miscible organic solvent |
Jun, 2029
(5 years from now) | |
US10220049 | BAUSCH | Topical pharmaceutical formulations containing a low concentration of benzoyl peroxide in suspension in water and a water-miscible organic solvent |
Jun, 2029
(5 years from now) | |
US8288434 | BAUSCH | Topical pharmaceutical formulations containing a low concentration of benzoyl peroxide in suspension in water and a water-miscible organic solvent |
Aug, 2029
(5 years from now) |
Drugs and Companies using BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE ingredient
Market Authorisation Date: 23 October, 2008
Treatment: Topical treatment of acne vulgaris in patients 12 years or older; Treatment of acne
Dosage: GEL;TOPICAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US5955109 | BAUSCH | Methods and compositions for topical delivery of retinoic acid |
Sep, 2016
(7 years ago) |
Drugs and Companies using TRETINOIN ingredient
Market Authorisation Date: 10 May, 2002
Treatment: Treatment of acne vulgaris
Dosage: GEL;TOPICAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US5955109 | BAUSCH | Methods and compositions for topical delivery of retinoic acid |
Sep, 2016
(7 years ago) |
Drugs and Companies using TRETINOIN ingredient
Market Authorisation Date: 10 May, 2002
Treatment: Treatment of acne vulgaris
Dosage: GEL;TOPICAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US5908838 | BAUSCH | Method for the treatment of acne |
Feb, 2018
(6 years ago) | |
US7790705 | BAUSCH | Minocycline oral dosage forms for the treatment of acne |
Jun, 2025
(1 year, 1 month from now) | |
US8252776 | BAUSCH | Minocycline oral dosage forms for the treatment of acne |
Jun, 2025
(1 year, 1 month from now) | |
US8268804 | BAUSCH | Minocycline oral dosage forms for the treatment of acne |
Jun, 2025
(1 year, 1 month from now) | |
US8722650 | BAUSCH | Extended-release minocycline dosage forms |
Jun, 2025
(1 year, 1 month from now) | |
US7919483 | BAUSCH | Method for the treatment of acne |
Mar, 2027
(2 years from now) | |
US7544373 | BAUSCH | Minocycline oral dosage forms for the treatment of acne |
Apr, 2027
(2 years from now) | |
US7541347 | BAUSCH | Minocycline oral dosage forms for the treatment of acne |
Apr, 2027
(2 years from now) | |
US9192615 | BAUSCH | Method for the treatment of acne and certain dosage forms thereof |
Nov, 2031
(7 years from now) |
Drugs and Companies using MINOCYCLINE HYDROCHLORIDE ingredient
Market Authorisation Date: 08 May, 2006
Treatment: Treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris; Treatment of acne
Dosage: TABLET, EXTENDED RELEASE;ORAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US5780676 | BAUSCH | Compounds having selective activity for Retinoid X Receptors, and means for modulation of processes mediated by Retinoid X Receptors |
Jul, 2015
(8 years ago) | |
US5962731 | BAUSCH | Compounds having selective activity for retinoid X receptors, and means for modulation of processes mediated by retinoid X receptors |
Oct, 2016
(7 years ago) |
Drugs and Companies using BEXAROTENE ingredient
Market Authorisation Date: 28 June, 2000
Treatment: Topical treatment of cutaneous lesions in patients with cutaneous t-cell lymphoma (stage ia and ib) who have refractory or persistent disease after other therapies or who have not tolerated other ther...
Dosage: GEL;TOPICAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US5476875 | BAUSCH | Catechol derivatives |
Dec, 2012
(11 years ago) |
Drugs and Companies using TOLCAPONE ingredient
Market Authorisation Date: 29 January, 1998
Treatment: Treatment of parkinson's disease
Dosage: TABLET;ORAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US5529791 | BAUSCH | Extended release form of diltiazem |
Jun, 2013
(10 years ago) |
Drugs and Companies using DILTIAZEM HYDROCHLORIDE ingredient
Market Authorisation Date: 11 September, 1995
Treatment: NA
Dosage: CAPSULE, EXTENDED RELEASE;ORAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US6765001 | BAUSCH | Compositions and methods for enhancing corticosteroid delivery |
Dec, 2021
(2 years ago) | |
US7794738 | BAUSCH | Compositions and methods for enhancing corticosteroid delivery |
Sep, 2022
(1 year, 7 months ago) | |
US7220424 | BAUSCH | Compositions and methods for enhancing corticosteroid delivery |
Jan, 2023
(1 year, 3 months ago) | |
US8232264 | BAUSCH | Compositions and methods for enhancing corticosteroid delivery |
Mar, 2023
(1 year, 1 month ago) |
Drugs and Companies using FLUOCINONIDE ingredient
Market Authorisation Date: 11 February, 2005
Treatment: Relief of the inflammatory and pruritic manifestations of corticosteroid responsive dermatoses in patients 12 years of age or older
Dosage: CREAM;TOPICAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US6150337 | BAUSCH | Specific modulation of Th1/Th2 cytokine expression by Ribavirin in activated T-lymphocytes |
Nov, 2017
(6 years ago) |
Drugs and Companies using RIBAVIRIN ingredient
Market Authorisation Date: 31 December, 1985
Treatment: Use of ribavirin to increase type 1 cytokine response and suppress type 2 cytokine resp0nse to lymphocytes, including methods that take advantage of such modulation to treat infections and infestation...
Dosage: FOR SOLUTION;INHALATION
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US6096341 | BAUSCH | Delayed release tablet of bupropion hydrochloride |
Oct, 2018
(5 years ago) |
Drugs and Companies using BUPROPION HYDROCHLORIDE ingredient
Market Authorisation Date: 28 August, 2003
Treatment: NA
Dosage: TABLET, EXTENDED RELEASE;ORAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
USRE39264 | BAUSCH | Pharmaceutical combination |
Aug, 2016
(7 years ago) | |
US6514980 | BAUSCH | Nucleoside analogs in combination therapy of herpes simplex infections |
Jul, 2018
(5 years ago) | |
US7223387 | BAUSCH | Antiviral formulations comprising propylene glycol and an isopropyl alkanoic acid ester |
Nov, 2022
(1 year, 5 months ago) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Patient Population(NPP) | Jan 22, 2017 |
New Combination(NC) | Jul 31, 2012 |
Drugs and Companies using ACYCLOVIR; HYDROCORTISONE ingredient
Market Authorisation Date: 31 July, 2009
Treatment: New combination product for the early treatment of recurrent herpes labialis (cold sores) to reduce the likelihood of ulcerative cold sores and to shorten the lesion healing time in adults and adolesc...
Dosage: CREAM;TOPICAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US5648093 | BAUSCH | Pharmaceutical and other dosage forms |
Jul, 2014
(9 years ago) | |
US6423342 | BAUSCH | Process for the preparation of a solid pharmaceutical dosage form |
Mar, 2016
(8 years ago) |
Drugs and Companies using SELEGILINE HYDROCHLORIDE ingredient
Market Authorisation Date: 14 June, 2006
Treatment: NA
Dosage: TABLET, ORALLY DISINTEGRATING;ORAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
USRE41134 | BAUSCH | Slow release vehicles for minimizing skin irritancy of topical compositions |
Feb, 2015
(9 years ago) | |
US6387383 | BAUSCH | Topical low-viscosity gel composition |
Aug, 2020
(3 years ago) |
Drugs and Companies using CLINDAMYCIN PHOSPHATE; TRETINOIN ingredient
Market Authorisation Date: 07 November, 2006
Treatment: Topical treatment of acne vulgaris; Topical treatment of acne vulgaris in patients 12 years or older
Dosage: GEL;TOPICAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10238645 | BAUSCH | Lower dosage strength imiquimod formulations and short dosing regimens for treating genital and perianal warts |
Aug, 2029
(5 years from now) | |
US8598196 | BAUSCH | Methods of treating dermatological disorders and inducing interferon biosynthesis with shorter durations of imiquimod therapy |
Aug, 2029
(5 years from now) | |
US10238644 | BAUSCH | 2×2×2 week dosing regimen for treating acting keratosis with pharmaceutical compositions formulated with 3.75% imiquimod |
Dec, 2029
(5 years from now) | |
US8222270 | BAUSCH | 2×2×2 week treatment regimen for treating actinic keratosis with pharmaceutical compositions formulated with 2.5% imiquimod |
Dec, 2029
(5 years from now) | |
US8299109 | BAUSCH | Method of treating actinic keratosis with 3.75% imiquimod cream |
Dec, 2029
(5 years from now) | |
US8236816 | BAUSCH | 2×2×2 week dosing regimen for treating actinic keratosis with pharmaceutical compositions formulated with 3.75 % imiquimod |
Dec, 2029
(5 years from now) | |
US11318130 | BAUSCH | 2x2x2 week dosing regimen for treating actinic keratosis with pharmaceutical compositions formulated with 3.75% imiquimod |
Dec, 2029
(5 years from now) | |
US11202752 | BAUSCH | Methods of treating dermatological disorders and inducing interferon biosynthesis with shorter durations of imiquimod therapy |
Apr, 2030
(6 years from now) | |
US10918635 | BAUSCH | Lower dosage strength imiquimod formulations and short dosing regimens for treating genital and perianal warts |
Apr, 2030
(6 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Product(NP) | Mar 25, 2013 |
New Indication(I-636) | Mar 24, 2014 |
New Strength(NS) | Jul 15, 2014 |
Drugs and Companies using IMIQUIMOD ingredient
Market Authorisation Date: 15 July, 2011
Treatment: Treatment of perianal warts; Treatment of actinic keratosis; Treatment of genital warts
Dosage: CREAM;TOPICAL